Open Access

RESIDENT’S CORNER

Oncogene targeted therapy for metastatic primary scrotal melanoma

Blair Stocks¹, Hunter Fuentes¹, Zachary McDowell¹, Michael Brooks^1,2, Jeffrey A. Jones^1,2

1 Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA
2 Michael E. DeBakey Veterans Administration Medical Center, Houston, Texas, USA
Address correspondence to Dr. Jeffrey A. Jones, Department of Urology, Baylor College of Medicine, 2002 Holcombe Blvd., Houston, TX 77030 USA

Canadian Journal of Urology 2021, 28(2), 10643-10647.

Abstract

Primary scrotal melanoma represents the rarest genitourinary malignancy. We describe the 25th reported case. The 79-year-old patient presented with a rapidly enlarging right cutaneous scrotal mass which after local excision demonstrated pT4b nodular malignant melanoma (BRAF V600E mutation positive). The patient underwent wide local excision of his hemiscrotum and inguinal lymph node dissection demonstrating nodes positive for melanoma (pN2b). Postoperatively, the patient developed a left sided malignant pleural effusion (M1b). Per American Joint Commission Cancer staging, BRAF mutant targeted therapy (dabrafenib) was initiated. This case documents the first instance in which metastatic scrotal melanoma will be treated with oncogene targeted therapy.

---

Keywords

---